Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-13. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
== Metabolic diseases == Early studies in the area reported that a liver-derived protein, alpha2-HS Glycoprotein, also known as Fetuin-A, can inhibit insulin tyrosine kinase activation and might play a role in the pathogenesis of metabolic disorders. Results suggest that hepatokine production could remodel metabolic homeostasis. This is exemplified by a number of studies revealing that hepatokines play a pivotal role in metabolism and contribute to the development of obesity, insulin resistance, T2D, NAFL, and NASH (109, 149). So far, ~20 hepatokines have been described to be involved in the regulation of energy and nutrient metabolism by acting directly on the liver or on distal target tissues. Hepatokines can be remodelled depending on the environment, for example, exercise-training can remodel hepatokine secretion. Little work in human hepatokines has been performed, however, using precision-cut liver slicing of human livers with and without MASH over 2000 hepatokines were described with potential roles in either promoting or protecting cardiometabolic disease pathogenesis. Hepatokines are now considered potential targets for the treatment of cardiometabolic disorders.
Negros is the second largest island in the Visayas (after Samar) and the fourth largest of the Philippines, with a total land area of 13,309.6 square kilometres (5,138.9 sq mi), similar to Flores or Jamaica. It is located between the islands of Panay and Guimaras to the west and Cebu to the east, with Siquijor located on the toe of the island and the islands of Bantayan to the north. Politically and linguistically, Negros is divided into two provinces: Negros Occidental and Negros Oriental. This division of the island, which roughly follows the mountain range in the center of the island, corresponds to the two related linguistic groups. The western half (Occidental) is home to the Hiligaynon Visayan-speaking population while the eastern half (Oriental) is home to the Cebuano Visayan-speaking population. Together, they are all called Negrenses. Kanlaon Volcano, located in the central-northern part of the island is the third most-active volcano in the Philippines and overlooks bordering communities and the city of Bacolod to the west. It is the highest peak of the whole island and of the Visayas. Other notable peaks on the island are Mount Silay and Mount Mandalagan in Negros Occidental and Mount Talinis (also known as Cuernos de Negros) in Negros Oriental. There are also lakes that dot the island, among the most notable are the Balinsasayao Twin Lakes in Negros Oriental. The volcanic activity in Negros is harnessed into electricity through two geothermal power plants in the island.
=== Rats === The copper level of rats that are exposed to crude oil noticeably shrank which indicates ejection of copper with lack of its absorption. Synthesis of catecholamine which enables total functions of body, emotions, and perception may be hindered by reduction of copper concentration. In addition to it, a rise in the activities of superoxide dismutase (SOD), chloramphenicol acetyltransferase (CAT), and glutathione S-transferase (GST) enzymes, in proportion to dose was seen in the rats, which were treated with BLCO for 21 days in a row. This phenomenon means induction of enzymes and especially in the case of GST, its increase may contribute to the availability of glutathione (GSH). Adedara and Farombi say that "Elevated level of intracellular hepatic GSH concentration observed in the BLCO-treated rats indicates an adaptive response to reduce damage and promote better survival under the conditions of oxidative stress induced by BLCO treatment". The elicitation of GSH in testes and sperm is controlled by BLCO. In contrast to rats treated for 21 days, the activities of those enzymes in rats exposed to BLCO for 45 days were decreased. Furthermore, in terms of sperms, noticeable shrink in mobility, number, and life/dead ratio was shown and total abnormality was elevated. However, abnormalities in sperms occurred by bonny light oil were able to be relieved with the help of vitamin E or quercetin. They have functions that restore normal hormonal levels and sperm parameters as well as inhibit oxidation.
=== Ratings === On FX, The Beauty premiered on January 21, 2026, drawing a total audience (P2+) of 512,400 viewers with a 0.16 rating, including 294,600 household viewers (0.23 rating). Subsequent episodes drew 297,900 viewers (0.09) on January 28, 183,000 (0.06) on February 4, and 206,000 (0.06) on February 11, followed by 266,000 viewers (0.08) on February 18 and 251,000 viewers (0.08) on February 25. The episode broadcast on March 4 drew 170,000 viewers (0.05), including 40,800 viewers aged 18–49 (0.03 rating), 37,700 viewers aged 25–54 (0.03 rating), and 166,500 household viewers (0.13 rating). Across this period, total viewership (P2+) ranged from 170,000 to 512,400 viewers, while ratings among adults aged 18–49 varied between 0.03 and 0.07. On streaming, The Beauty ranked No. 1 on Hulu's "Top 15 Today" list—a daily ranking of the platform's most-watched titles—on January 23, 2026, and remained on the chart through March 6, 2026.
Sources: en.wikipedia.org
On June 11, 2009, Blabbermouth.net reported that the new album would be titled Black Gives Way to Blue and was officially set to be released on September 29, 2009. The title first appeared on Amazon.com without any prior announcement from the band. In addition, it was announced that Elton John plays piano on the title track, a tribute to Layne Staley written and sung by Cantrell. The album features new vocalist and rhythm guitarist William DuVall sharing vocal duties with lead guitarist/vocalist Jerry Cantrell, who sings lead vocals on most of the songs. DuVall sings lead vocals on the song "Last of My Kind".
The Colombian government initially blamed drug lord Pablo Escobar for the murder, but journalist Steven Dudley argues that many in the UP pointed at then-Interior Minister Carlos Lemos Simmonds for publicly calling out the UP as the "political wing of FARC" shortly before the murder, while others claimed it was the result of an alliance between Fidel Castaño, members of the Colombian military, and the DAS. Pecáut and Dudley argue that significant tensions had emerged between Jaramillo, FARC, and the Communist Party due to the candidate's recent criticism of the armed struggle and their debates over the rebels' use of kidnapping, almost leading to a formal break. Jaramillo's death led to a large exodus of UP militants; in addition, by then many FARC cadres who had joined the party had already returned to clandestinity, using the UP experience as an argument in favor of revolutionary war. The M-19 and several smaller guerrilla groups were successfully incorporated into a peace process as the 1980s ended and the 1990s began, which culminated in the elections for a Constituent Assembly of Colombia that would write a new constitution, which took effect in 1991. Contacts with the FARC, which had irregularly continued despite the end of the ceasefire and the official 1987 break from negotiations, were temporarily cut off in 1990 under the presidency of César Gaviria Trujillo (1990–1994).
A Komodo dragon may attempt to speed up the process by ramming the carcass against a tree to force it down its throat, sometimes ramming so forcefully that the tree is knocked down. A small tube under the tongue that connects to the lungs allows it to breathe while swallowing. After eating up to 80% of its body mass in one meal, it drags itself to a sunny location to speed digestion, as the food could rot and poison the dragon if left undigested in its stomach for too long. Because of their slow metabolism, large dragons can survive on as few as 12 meals a year. After digestion, the Komodo dragon regurgitates a mass of horns, hair, and teeth known as the gastric pellet, which is covered in malodorous mucus. After regurgitating the gastric pellet, it rubs its face in the dirt or on bushes to get rid of the mucus.
=== Yeast and bacteria === Unlike humans, yeast and bacteria (except lactic acid bacteria, and E. coli in certain conditions) do not ferment glucose to lactate. Instead, they ferment it to ethanol and CO2. The overall reaction can be seen below:
The ELP can be conjugated to a functional group that can bind to a protein of interest. At temperatures below the Tt, the ELP will bind to the ligand in its linear form. In this linear state, the ELP-protein complex cannot easily be distinguished from the extraneous proteins in the solution. However, once the solution is heated to a temperature exceeding the Tt, the ELP will form spherical clumps. These clumps will then settle to the bottom of the solution tube following centrifugation, carrying the protein of interest. The proteins that are not needed will be found in the supernatant, which can be physically separated from the spherical aggregates. To ensure that there are few impurities in the ELP-protein complex isolated, the solution can be cooled below the Tt, enabling the ELPs to once again assume their linear structure. From this point, hot and cold centrifugation cycles can be repeated, and then the protein of interest can be eluted from the ELPs via the addition of a salt.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.